Davis Rea LTD. Purchases 20,268 Shares of Zoetis Inc. $ZTS

Davis Rea LTD. lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 96.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,239 shares of the company’s stock after purchasing an additional 20,268 shares during the period. Zoetis comprises 1.6% of Davis Rea LTD.’s investment portfolio, making the stock its 19th largest holding. Davis Rea LTD.’s holdings in Zoetis were worth $6,431,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC lifted its stake in shares of Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of Zoetis by 11.1% in the first quarter. Farther Finance Advisors LLC now owns 4,738 shares of the company’s stock worth $767,000 after acquiring an additional 474 shares during the period. Simplicity Wealth LLC lifted its stake in shares of Zoetis by 16.2% in the first quarter. Simplicity Wealth LLC now owns 1,709 shares of the company’s stock worth $281,000 after acquiring an additional 238 shares during the period. SG Americas Securities LLC lifted its stake in shares of Zoetis by 61.8% in the first quarter. SG Americas Securities LLC now owns 20,782 shares of the company’s stock worth $3,422,000 after acquiring an additional 7,940 shares during the period. Finally, Simon Quick Advisors LLC lifted its stake in shares of Zoetis by 60.3% in the first quarter. Simon Quick Advisors LLC now owns 4,835 shares of the company’s stock worth $796,000 after acquiring an additional 1,818 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ZTS. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Argus reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Finally, Piper Sandler lifted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and an average target price of $196.71.

Zoetis Price Performance

Shares of ZTS opened at $141.05 on Friday. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $196.55. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The business’s 50 day moving average price is $149.24 and its two-hundred day moving average price is $154.46. The firm has a market cap of $62.51 billion, a PE ratio of 24.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period in the previous year, the firm earned $1.56 earnings per share. The company’s revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Zoetis’s payout ratio is currently 34.42%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.